# Nanjing King-friend Biochemical Pharmaceutical Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/nanjing-king-friend-biochemical-pharmaceutical-co

- Industry: Pharmaceuticals
- Headquarters: Nanjing, China
- Website: www.nkf-pharma.com
- Total disclosed funding: $43M
- Latest round: Series A (May 10, 2011)
- Investors on record: 3

## About

Nanjing King-friend Biochemical Pharmaceutical Co., Ltd focuses on developing and manufacturing biopharmaceuticals and health supplements, offering innovative medical solutions aimed at enhancing patient outcomes through advanced therapeutic products.Founded in 2000 in Nanjing, China, Nanjing King-friend Biochemical Pharmaceutical Co., Ltd specializes in biopharmaceuticals. The company successfully transitioned to public trading with an IPO on July 19, 2017, raising CNY 457.8 million by selling 63.5 million shares at CNY 7.21 each. The founder's background is not specified, and there are currently no records of subsidiaries or previous mergers.Nanjing King-friend Biochemical Pharmaceutical Co., Ltd specializes in the development and manufacturing of pharmaceutical products, particularly in biopharmaceuticals and health supplements. Their core offerings include biologics such as monoclonal antibodies and recombinant proteins, targeting diseases like cancer and autoimmune disorders. The company primarily serves hospitals, healthcare providers, and research institutions, with distribution channels extending to Europe and North America, supporting clinical research and patient care.In 2021, Nanjing King-friend Biochemical Pharmaceutical Co., Ltd reported a revenue of CNY 571,441,346.7 with an EBITDA of CNY 197,650,367.7. Revenue is generated through direct sales to healthcare providers and research institutions, utilizing a B2B model for consistent product supply. Pricing aligns with the advanced technology and efficacy of their therapeutics.Nanjing King-friend Biochemical Pharmaceutical Co., Ltd plans to expand its product line with new biopharmaceuticals to be launched by 2024, targeting specific therapeutic areas. They aim to penetrate new markets in Southeast Asia and Latin America within the next three years. The recent IPO funding of CNY 457.8 million will support these initiatives, facilitating research and development for upcoming products and enhancing market entry strategies.

## Funding rounds

- Series A, May 10, 2011, $43M — Vivo Capital, Oriental Fortune Capital, MPC
- Angel, Jan 1, 2010 — MPC

## Investors

- MPC — Angel, Series A
- Vivo Capital (https://capitalatlas.ai/funds/vivo-capital) — Series A
- Oriental Fortune Capital (https://capitalatlas.ai/funds/oriental-fortune-capital) — Series A